

29TH
ANNUAL

New Treatments in Chronic Liver Disease

FRIDAY, MARCH 28 – SUNDAY, MARCH 30, 2014

Pre-Conference: Friday, March 28, 2014

Main Conference: Saturday, March 29 – Sunday, March 30, 2014

Hilton La Jolla Torrey Pines, La Jolla, California

course overview

This CME conference will review new medications and therapies that are now available, or will soon be available, and discuss their comparative values. The results of trials using new drugs to treat chronic viral hepatitis B and C, non-alcoholic fatty liver diseases, cholangiocarcinoma, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular carcinoma and complications of end-stage liver disease will be reviewed in detail. New Treatments in Chronic Liver Disease is a comprehensive yet concise program for updating physicians on these and other commonly encountered problems in the treatment of liver diseases.

There was a fundamental change in the treatment of chronic hepatitis C in 2014 with the addition of 2 new direct-acting antiviral (DAA's) drugs to current standard of care for all genotypes. There will be two separate lectures devoted to this topic this year. The first will be on triple therapies that were approved in late 2013. The second will be on future therapies using two or more DAA's without interferons.

We anticipate that there will be a number of new demands placed on treatment providers, including screening, access to treatment, costs of therapy and the continuation of complex algorithms for interferon-based regimens. Looking beyond 2014, we see numerous combinations of DAA's in development including protease inhibitors, nucleoside polymerase inhibitors, non-nucleoside polymerase inhibitors and NS5A inhibitors. All of these agents are in phase 3 development and a number have completed studies and are awaiting FDA review. In hepatitis B, the treatments have not changed but there is more mature data available on renal resistance, long-term HBsAg loss and clinical outcomes. The addition of hepatitis E as an important disease and a treatable form of viral hepatitis has been included in this year's program. New therapies for NAFLD and NASH are in development and will be explored. The explosive growth of NASH in the US has created a significant need for effective drug therapy. The diagnosis and treatment of hepatocellular carcinoma will be updated as this disease is one of the few cancers with a growing incidence in the US. New oral therapy is moving this field forward. There will be an update on management of hepatic encephalopathy, hyponatremia and the management of pulmonary complications in the transplant candidate.

NEW! Conference presentations (pre and main) will be available via mobile app and conference website. You are able to download, save and/or print these presentations from the mobile app and conference website onto your tablet, laptop or smart phone. Attendees will receive an email prior to the conference with directions on how to access the mobile app and conference website and how to download the presentations. You will also want to bring your tablet, laptop or smart phone with you to the conference. Internet will be available in the meeting space.

educational objectives

After participating in this course, attendees should be able to:

- Understand the details of the AASLD guidelines for treatment of HCV using DAA's in combination with pegylated interferon and ribavirin or in IFN-free regimens
- Review our current knowledge of NAFLD and non-alcoholic steatohepatitis and explore the use of new agents and approaches to treatment of the conditions.
- Integrate the algorithm for a therapeutic approach to treatment of HBV and HEV using anti-virals.
- Discuss novel therapies for HCV including NSSA, protease and polymerase inhibitors and cyclophilin inhibitors.
- Update the skills and management required for transplant hepatology.
- Apply current options of therapy for hepatocellular carcinoma to determine the best approach for your patients.
- Discuss new treatment paradigms for HCV direct-acting antiviral drugs.
- Recognize the impact of NAFLD and NASH in the US and consider new treatment options for these patients.
- Describe the diagnosis and treatment of PBC, PSC and cholangiocarcinoma.
- Integrate treatment options discussed for patients with ESLD due to alcohol who have complicating factors such as HCV, NASH or inherited genetic disorder.
- Discuss the issues complicating drug treatment in decompensated cirrhosis, hepatic encephalopathy and hyponatremia.
- Review the management of pulmonary/cardiac complications of ESLD.

course director

Paul Pockros, MD, FACC
Director, Liver Disease Center
Division of Gastroenterology/Hepatology
Scripps Clinic
Clinical Director of Research
Scripps Translational Science Institute
La Jolla, California

scripps faculty

Catherine Frenette, MD
Medical Director of Liver Transplantation and
Director of Center of Excellence for HCC
Scripps Center for Cell and
Organ Transplantation
Scripps Clinic
La Jolla, California

Jill Lane, MD
Division of Gastroenterology/Hepatology
Scripps Clinic
La Jolla, California

Andrea Scherschel, NP
Division of Gastroenterology/Hepatology
Scripps Clinic
La Jolla, California

guest faculty

Robert Gish, MD
Principle
Robert G. Gish Consultants LLC
San Diego, California

Kris Kowdley, MD, FACP, FACC, FGAF
Director,
Liver Center of Excellence in the
Digestive Disease Institute
Virginia Mason Medical Center
Clinical Professor of Medicine,
University of Washington, Seattle
Seattle, Washington

Keith Lindor, MD, FACC
Executive Vice Provost and Dean
College of Health Solutions
Arizona State University
Phoenix, Arizona

Michael Schilsky, MD
Associate Professor of Medicine (Digestive
Diseases) and of Surgery (Transplant)
Medical Director, Adult Liver Transplant
Yale-New Haven Transplantation Center
New Haven, Connecticut

Norman Sussman, MD
Associate Professor, Liver Center
Baylor College of Medicine
Houston, Texas

**Zobair Younossi, MD, MPH, FACC,
FACP, AGAF**
Chairman, Department of Medicine
Inova Fairfax Hospital
Vice President for Research
Inova Health System
Professor of Medicine, VCU-Inova Campus
Falls Church, Virginia

Faculty Disclosure

In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Employees of a commercial interest with business lines or products relating to the content of the CME activity will not participate in the planning or any accredited portion of the conference. Disclosure will be made to all participants at the conference location, prior to the educational activity commencement.

pre-conference overview

We will review the virology, genotypes, modes of infection of HCV and characteristics of the clinical illness caused by acute and chronic infections. Tests for HCV, including PCR assays and genotyping, interpretations and indications for liver biopsies and complications of cirrhosis will all be discussed. We will show how to initiate and monitor patients during treatment with simeprevir and sofosbuvir, manage side effects of therapy and deal with various patient populations including African Americans, HIV-coinfected and ESLD patients. Lastly, new drugs in development including protease inhibitors, other nucleoside and non-nucleoside polymerase inhibitors, NS5A inhibitors, and other novel agents will be discussed.

pre-conference

Friday, March 28, 2014

- 12:30 p.m. Registration & View Exhibits
- 1 p.m. Welcome & Introduction
Paul Pockros, MD
- 1:10 p.m. **Update on HCV Diagnostics**
Paul Pockros, MD
- 1:40 p.m. **Update on Current therapy with PEG IFN-based regimens**
Paul Pockros, MD
- 2:40 p.m. Break & View Exhibits
- 3 p.m. **ESLD and HCC**
Catherine Frenette, MD
- 3:30 p.m. **Case Presentation, Discussion and Q&A**
- Side-Effects Management
 - Selection of Treatment
 - Cirrhosis: Who to Treat
 - Special Populations
- Andrea Scherschel, NP*
- 5 p.m. Adjourn

main conference

Saturday, March 29, 2014

- 7:30 a.m. Registration, Breakfast & View Exhibits
- 8 a.m. Welcome & Introduction
Paul Pockros, MD
- MODERATOR**
Catherine Frenette, MD
- 8:15 a.m. **PEG-IFN Based Regimens for HCV**
Paul Pockros, MD
- 9 a.m. **IFN-Free Therapies in Development**
Kris Kowdley, MD
- 9:45 a.m. Break & View Exhibits
- 10:15 a.m. **Updates on HBV and HEV**
Robert Gish, MD
- Debate**
Treat with Triple Therapy Regimens Now or Wait?
- 11 a.m. **Now:** *Kris Kowdley, MD*
Wait: *Paul Pockros, MD*
- 11:10 a.m. **Panel Discussion: Morning Speakers**

Saturday, March 29, 2014 *(continued)*

- 11:45 a.m. Lunch
- MODERATOR**
Paul Pockros, MD
- 1 p.m. **NAFLD and NASH**
Zobair Younossi, MD
- HAUBRICH LECTURER**
- 1:45 p.m. **PBC and PSC**
Keith Lindor, MD
- 2:30 p.m. Break & View Exhibits
- Debate #1:**
Hepatitis C Drugs Cost Too Much!
- 3 p.m. **Yes:** *Kris Kowdley, MD*
No: *Paul Pockros, MD*
- Debate #2:**
NAFLD is a Behavioral Disease Rather Than a Liver Disease
- 3:15 p.m. **I agree:** *Robert Gish, MD*
3:20 p.m. **I do not agree:** *Zobair Younossi, MD*
- 3:30 p.m. **Panel Discussion: Afternoon Speakers**
- 4:30 p.m. Adjourn

Sunday, March 30, 2014

- 7:30 a.m. Breakfast & View Exhibits
- MODERATOR**
Jill Lane, MD
- 8 a.m. **Update on Wilson's Disease**
Michael Schilsky, MD
- 8:45 a.m. **End Stage Liver Disease: Pitfalls of Management**
Norman Sussman, MD
- 9:30 a.m. **HCC**
Catherine Frenette, MD
- 10:15 a.m. Break & View Exhibits
- Debate #1:**
Are We Doing This Fairly? MELD Exception and Share 35
- 10:30 a.m. **Yes:** *Michael Schilsky, MD*
10:35 a.m. **No:** *Norman Sussman, MD*
- Debate #2:**
How do we improve HCC screening?
- 10:45 a.m. **Incentives:** *Michael Schilsky, MD*
10:50 a.m. **Punitive Measures:** *Catherine Frenette, MD*
- 11 a.m. **Panel Discussion**
- 11:45 a.m. Adjournment



William S. Haubrich Distinguished Lecturer

accreditation & disclosures

Keith Lindor, MD



Keith Lindor, M.D. is Executive Vice Provost and Dean of the College of Health Solutions at Arizona State University. Dr. Lindor served as the Dean of the Mayo Medical School from 2005-2011 where he was also a Professor of Medicine in the Division of Gastroenterology and Hepatology at the Mayo Clinic College of Medicine in Rochester, Minnesota. Dr. Lindor received a Bachelor's of Chemistry degree from the University of Minnesota and his MD degree from Mayo Medical School. Following this, he was a resident in internal medicine at Bowman Grey School of Medicine of Wake Forest University. Before starting his Gastroenterology Fellowship at Mayo, he served a year in the Indian Health Service in Southern Arizona.

Dr. Lindor's clinical interests include cholestatic liver diseases in adults, particularly primary biliary cirrhosis and primary sclerosing cholangitis as well as nonalcoholic steatohepatitis. The focus of his research work is primarily on clinical trials and means of optimizing the medical management of patients with these disorders.

In his work at Arizona State University he focuses on means to improve the health of the population, while lowering costs and enhancing access. This work's emphasis is on health rather than health care with the prospect of different interprofessional delivery models as payment systems change. Dr. Lindor has served as Editor-in-Chief of Hepatology and as Senior Associate Editor for Clinical Gastroenterology and Hepatology. He serves on the governing board of the American Association for the Study of Liver Disease.

William S. Haubrich, MD



Dr. Haubrich graduated from Franklin & Marshall College in Lancaster, Pennsylvania in 1943 and from the medical school of Case-Western Reserve University in Cleveland, Ohio in 1947. His postgraduate training in pathology and internal medicine was at Cleveland City Hospital (now MetroHealth). His mentor in gastroenterology was Dr. Henry L. Bockus at the Graduate Hospital of the University of Pennsylvania in Philadelphia. During the Korean War he served as gastroenterologist to the Madigan Army Hospital at Fort Lewis, Washington. From 1955 to 1970 he was on the gastroenterology staff at the Henry Ford Hospital in Detroit. In 1970 he was appointed Clinical Member at the Scripps Clinic and Research Foundation where he headed the division of gastroenterology from 1972 to 1984. He has served as Clinical Professor of Medicine at the University of California, San Diego since 1971. His scholarly contributions include more than 200 journal articles and textbook chapters. He was consultant in life sciences to the editors of the 3rd and 4th editions of the American Heritage Dictionary of the English Language. In 1960 he was awarded the Vincent Lyon Prize by the American Gastroenterology Association and in 1985 received the Rudolf Schindler Award of the American Society of Gastrointestinal Endoscopy. He was named a Master of the American College of Physicians. Dr. Haubrich passed away peacefully at his home in La Jolla in October 2012.

accreditation

Scripps Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Scripps Health designates this live activity for a maximum of **13.25 AMA PRA Category 1 Credit(s)TM**. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit Breakdown:

Pre-Conference (Fri): 3.5

Main Conference (Sat-Sun): 9.75

Nurses: The California State Board of Registered Nurses (BRN) accepts AMA PRA Category 1 Credit(s)TM as meeting continuing education requirements for license renewal. Most state Boards of Registered Nurses accept AMA PRA Category 1 Credit(s)TM as meeting continuing education requirements for license renewal. Nurses should check with their state board regarding use of CME credit.

Nurse Practitioners: This program will be submitted to the American Academy of Nurse Practitioners for continuing education credit.

Physicians Assistants: The American Academy of Physician Assistants accepts Category 1 credit from AMA Category 1 CME organizations accredited by ACCME.

Pharmacists: This conference meets CE Standards for Pharmacists by the California State Board of Pharmacy.

conference location



Hilton La Jolla Torrey Pines

10950 North Torrey Pines Road, La Jolla, CA 92037

Reservations: 1-800-445-8667

Hotel Direct: 858-558-1500

Rates & Reservations

Please make your own reservations and mention the Scripps Liver Disease Conference to receive the reduced rate of \$199 per night (excludes tax). A block of rooms will be held for Scripps until **Thursday, March 6, 2014**. After this date, reservations will be accepted on a space and rate available basis only. Scripps discounted rooms come with:

- Complimentary internet in guest rooms
- Discounted overnight self and valet parking

Please note: Attendees who book their room through an online, third-party service (Hotels.com®, Expedia.com®, Priceline.com®, etc.) are not eligible to receive the amenities listed above.

educational grants

This course is supported, in part, by educational grants from industry, in accordance with ACCME accreditation Standards for Commercial Support. At the time of printing, a complete listing of commercial supporters was not available. Appropriate acknowledgment will be given to all supporters at the time of the educational activity.

cultural and linguistic competency

This activity is in compliance with California Assembly Bill 1195 which requires that all CME activities comprising a patient care element include curriculum addressing the topic of cultural and linguistic competency. The intent of this bill is to ensure that health care professionals are able to meet the cultural and linguistic concerns of a diverse patient population through effective and appropriate professional development. Cultural and linguistic competency was incorporated into the planning of this activity.

exhibit and support opportunities

For information on exhibit and support opportunities during this and many other Scripps educational conferences, please contact:

Scripps Conference Services & CME

Phone: 858-652-5400

Email: med.edu@scrippshealth.org

www.scripps.org/conferenceservices

New Treatments in Chronic Liver Disease

pre-conference fees

Included: Course tuition, access to conference materials (via mobile app and conference website) and internet in meeting space.

Not Included: Printed course syllabus (presentations available via mobile app and conference website), meals, travel costs, parking and lodging.

	Thru Feb 21	Feb 22 - Mar 25	On-site after Mar 25
	_____ \$100	_____ \$125	_____ \$150

main conference fees

Included: Course tuition, access to conference materials (via mobile app and conference website) internet in meeting space, breakfast, breaks and lunch.

Not Included: Printed course syllabus (presentations available via mobile app and conference website), travel costs, parking, lodging and dinner.

	Thru Feb 21	Feb 22 - Mar 25	On-site after Mar 25
Physicians	_____ \$305	_____ \$330	_____ \$355
Nurses/Nurse Practitioners/Physician Assistant/ Pharmacist/Allied Health Professionals	_____ \$235	_____ \$260	_____ \$285
Fellows and Residents	_____ \$165	_____ \$190	_____ \$215

Please note: there are no day rates available for this conference.

By completing this registration form and returning it to Scripps you are acknowledging compliance with all attendance policies.

Do you give permission to publish your name and e-mail address to be distributed at the conference?

Yes No

Please Print Clearly. Should we have any conference communications or updates please provide your direct contact information.

FIRST NAME, MI, LAST NAME DEGREE (MD, DO, PHD, RN, ETC)

BADGE NAME (IF DIFFERENT FROM ABOVE)

AFFILIATION/HOSPITAL/COMPANY SPECIALTY

DIRECT MAILING ADDRESS

CITY/STATE / ZIP CODE

DIRECT TELEPHONE FAX

EMAIL (This is required and will be your user name when accessing your online account.)

ASSISTANT NAME ASSISTANT DIRECT TELEPHONE

ASSISTANT E-MAIL



PLEASE INDICATE ANY SPECIAL NEEDS (INCLUDING DIETARY RESTRICTIONS)
Special requests will be considered and accommodated in full compliance with the Americans with Disabilities Act (ADA).

Office Use Only: Date Received Amount Check No. / Approval CD Confirmation Sent Initials

Payment method

Check Please make checks payable to Scripps (in U.S. dollars only).

If paying by credit card, please fill out the information below. Visa MasterCard AMEX Discover

CREDIT CARD NUMBER EXPIRATION DATE SECURITY CODE ON CARD (required)

NAME ON CARD AUTHORIZED SIGNATURE

BILLING ADDRESS IF DIFFERENT FROM ABOVE

three ways to register

Online scripps.org/conferenceservices

Fax 858-652-5565

Mail Scripps Conference Services & CME
11025 North Torrey Pines Road
Suite 200, Maildrop: SCRC 200
La Jolla, California 92037

questions?

Contact Scripps Conference Services & CME

Phone 858-652-5400

Email med.edu@scrippshealth.org

Attendance Policies Registration Confirmation

A confirmation letter will be e-mailed to you upon receipt of the conference registration form and payment. If you have not received it within two weeks, please contact the Scripps Conference Services & CME office.

Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$100 processing fee for the main conference (\$40 for Fellows and Residents) and \$20 processing fee for the pre-conference, if your cancellation is received in writing no later than March 18, 2014. Attendee substitutions are allowed, but notification must be made in writing by March 18, 2014. After this date, under no circumstances will refunds, credits, or substitutions be granted. No refunds or credits will be given to "no shows."

Guest Attendance Policy

All conference activities (including educational sessions, meal functions, exhibit hall, etc.) are exclusively reserved for conference attendees. Non-registered guests (including children, family members, colleagues, etc.) are not allowed in the conference areas. Badges provided at registration are required for entrance into all functions and will be strictly enforced.

Scripps Conference Modification or Cancellation

Scripps reserves the right to modify the course's schedule or program as necessary. Scripps also reserves the right to cancel this conference, in which case a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of Scripps cancellation.

Recording and Photography Clause

Scripps reserves exclusive rights to record (audio and video) and/or photograph all conference proceedings for use in marketing materials, presentations and course content sales.

29TH
ANNUAL

New Treatments in Chronic Liver Disease

MARCH 28-30, 2014

Pre-Conference: Friday, March 28, 2014

Main Conference: Saturday, March 29 - Sunday, March 30, 2014

Hilton La Jolla Torrey Pines, La Jolla, California

2014 Conference Highlights

- NEW! Conference presentations (pre and main) will be available via mobile app and conference website. You are able to download, save and/or print these presentations from the mobile app and conference website onto your tablet, laptop or smart phone. Attendees will receive an email prior to the conference with directions on how to access the mobile app and conference website and how to download the presentations. You will also want to bring your tablet, laptop or smart phone with you to the conference. Internet will be available in the meeting space.
- Half Day Pre-Conference Seminar reviewing the virology, geno- types and modes of infection of HCV. Participants will learn the details of new AASLD guidelines for treatment of HCV using DAA's in combination with pegylated interferon and ribavirin.
- Comprehensive presentations of the latest advances in hepatology with renowned faculty chosen for their expertise as well as teaching skills.
- Endorsed by the American College of Gastroenterology.
- Attendees will have opportunities to network with each other and interact with speakers to discuss topics from the course.

target audience

- Hepatologists
- Gastroenterologists
- Infectious Disease Specialists
- Nurse Practitioners
- Physician Assistants
- Nurses
- Residents/Fellows
- and others desiring an update in these specialty areas

**Friday,
March 28**
Pre-Conference
Seminar!

29TH
ANNUAL

New Treatments in Chronic Liver Disease

MARCH 28-30, 2014

Pre-Conference: Friday, March 28, 2014

Main Conference: Sat., March 29 - Sun., March 30, 2014

Hilton La Jolla Torrey Pines, La Jolla, California